{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T13:39:46Z","timestamp":1765805986940},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T00:00:00Z","timestamp":1602460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Mucormycosis is one of the most complicated to diagnose and treat invasive fungal diseases. Diagnostic techniques have not significantly advanced in years, and recent international consensus treatment guidelines offer some insight into the current best approaches to treating this deadly invasive mold.<\/jats:p>","DOI":"10.1093\/jpids\/piaa106","type":"journal-article","created":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T19:15:56Z","timestamp":1601320556000},"page":"640-644","source":"Crossref","is-referenced-by-count":5,"title":["Latest Thoughts on Treating Pediatric Mucormycosis"],"prefix":"10.1093","volume":"9","author":[{"given":"William J","family":"Steinbach","sequence":"first","affiliation":[{"name":"Division of Pediatric Infectious Diseases, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina, USA"},{"name":"Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, USA"},{"name":"Duke Pediatric Immunocompromised Host Program, Durham, North Carolina, USA"},{"name":"International Pediatric Fungal Network, Duke University Medical Center, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,10,12]]},"reference":[{"key":"2020111005230131900_CIT0001","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1086\/430710","article-title":"Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer","volume":"41","author":"Chamilos","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2020111005230131900_CIT0002","doi-asserted-by":"crossref","first-page":"684.e611","DOI":"10.1016\/j.cmi.2015.03.019","article-title":"Comparison of computed tomographic findings in pulmonary mucormycosis and invasive pulmonary aspergillosis","volume":"21","author":"Jung","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"2020111005230131900_CIT0003","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3390\/microorganisms7110531","article-title":"Comparison of clinical manifestation, diagnosis, and outcomes of invasive pulmonary aspergillosis and pulmonary mucormycosis","volume":"7","author":"Lin","year":"2019","journal-title":"Microorganisms"},{"key":"2020111005230131900_CIT0004","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/jpids\/piu074","article-title":"A prospective, international cohort study of invasive mold infections in children","volume":"4","author":"Wattier","year":"2015","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2020111005230131900_CIT0005","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1056\/NEJM197907193010303","article-title":"A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis","volume":"301","author":"Bennett","year":"1979","journal-title":"N Engl J Med"},{"key":"2020111005230131900_CIT0006","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","article-title":"Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium","volume":"19","author":"Cornely","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2020111005230131900_CIT0007","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica"},{"key":"2020111005230131900_CIT0008","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1128\/AAC.45.12.3487-3496.2001","article-title":"Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study","volume":"45","author":"Walsh","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"2020111005230131900_CIT0009","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1093\/jac\/dkv236","article-title":"Prospective pilot study of high-dose (10 mg\/kg\/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis","volume":"70","author":"Lanternier","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2020111005230131900_CIT0010","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2020111005230131900_CIT0011","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1128\/AAC.49.2.721-727.2005","article-title":"Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis","volume":"49","author":"Ibrahim","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2020111005230131900_CIT0012","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1128\/AAC.49.2.830-832.2005","article-title":"Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice","volume":"49","author":"Spellberg","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2020111005230131900_CIT0013","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1128\/AAC.01458-07","article-title":"Combination echinocandin-polyene treatment of murine mucormycosis","volume":"52","author":"Ibrahim","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2020111005230131900_CIT0014","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1086\/589857","article-title":"Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis","volume":"47","author":"Reed","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2020111005230131900_CIT0015","doi-asserted-by":"crossref","first-page":"811.e811","DOI":"10.1016\/j.cmi.2016.03.029","article-title":"Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis","volume":"22","author":"Kyvernitakis","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"2020111005230131900_CIT0016","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.3324\/haematol.2012.083063","article-title":"Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries","volume":"98","author":"Pagano","year":"2013","journal-title":"Haematologica"},{"key":"2020111005230131900_CIT0017","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/myc.12222","article-title":"Stability in the cumulative incidence, severity and mortality of 101 cases of invasive mucormycosis in high-risk patients from 1995 to 2011: a comparison of eras immediately before and after the availability of voriconazole and echinocandin-amphotericin combination therapies","volume":"57","author":"Abidi","year":"2014","journal-title":"Mycoses"},{"key":"2020111005230131900_CIT0018","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1128\/AAC.50.1.96-103.2006","article-title":"Lovastatin has significant activity against Zygomycetes and interacts synergistically with voriconazole","volume":"50","author":"Chamilos","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2020111005230131900_CIT0019","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1093\/jac\/dkz102","article-title":"In vitro interactions between isavuconazole and tacrolimus, cyclosporin A or sirolimus against Mucorales","volume":"74","author":"Schwarz","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2020111005230131900_CIT0020","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1093\/jac\/dkl350","article-title":"Deferiprone iron chelation as a novel therapy for experimental mucormycosis","volume":"58","author":"Ibrahim","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"2020111005230131900_CIT0021","doi-asserted-by":"crossref","first-page":"e00266-19","DOI":"10.1128\/AAC.00266-19","article-title":"In vitro activity of combinations of zinc chelators with amphotericin B and posaconazole against six Mucorales species","volume":"63","author":"Leonardelli","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2020111005230131900_CIT0022","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/myc.13028","article-title":"High-dose posaconazole for azole-resistant aspergillosis and other difficult-to-treat mould infections","volume":"63","author":"Schauwvlieghe","year":"2020","journal-title":"Mycoses"},{"key":"2020111005230131900_CIT0023","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1093\/jac\/dkz344","article-title":"Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn)","volume":"74","author":"Salmanton-Garc\u00eda","year":"2019","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of the Pediatric Infectious Diseases Society"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jpids\/article-pdf\/9\/5\/640\/34220176\/piaa106.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jpids\/article-pdf\/9\/5\/640\/34220176\/piaa106.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T10:23:30Z","timestamp":1605003810000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpids\/article\/9\/5\/640\/5921022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,12]]},"references-count":23,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,10,12]]},"published-print":{"date-parts":[[2020,11,10]]}},"URL":"https:\/\/doi.org\/10.1093\/jpids\/piaa106","relation":{},"ISSN":["2048-7207"],"issn-type":[{"value":"2048-7207","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,11]]},"published":{"date-parts":[[2020,10,12]]}}}